Sustainability Report 2014 Lek d.d.

Company Profile Sustainability Report 2014 – Lek d.d. 14 Company headquarters The Ljubljana site also features the company headquarters with a number of specialist services: Finance, Sales and Marketing, Procurement, Supply, Quality, Human Resources, Legal Affairs, HSE, Corporate Communication and others. Ivo Aebischer, site Head Steriles in 2014, Ljubljana Obrat Viale 2 Specifics of production in a sterile environment and new production of lyophilized vials "The production of sterile products is very demanding, mainly due to the working conditions which must assure the sterility of the final product. The first and most im- portant condition is proper training of the associates. At Lek, we have been building the knowledge about sterile production for over a decade and it has been continuously updated, mainly due to increasing require- ments regarding quality. It was the knowledge of all employees at the Steriles production that placed us among the key technological production sites within Sandoz and the entire Novartis network." Investment Sterile dosage forms The Sterile Pharmaceutical Products unit continues to in- crease production output in all three areas: vials, ampules and liquid products. This was mainly driven by: • opening of a new facility for lyophilized vials (Vials 2) which doubled the existing capacity, • production of a leading ampule product for Novartis Pharma, • successful launching of a new nasal spray mometa- sone in the EU. We reconfirmed the importance of the Steriles unit within the Sandoz global production network and our role as a center of excellence for production of lyophilized vials and ampules. New facility for liquid products After the successful completion of the Vials 2 invest- ment project, we focused in 2014 on a key strategic project, a new plant for liquid products. More than 30 associates are involved in the project and regular production is planned in mid-2015. The decision for this new investment is the result of a highly successful launching of mometasone nasal spray in the EU markets. The new facility will be an independent production unit, consisting of the prepa- ration of solutions, new, state-of-the-art filling lines and related secondary packaging lines. With this new plant for liquid products we will increase capacity by 18 million liquid products and gain a tech- nological platform for nasal sprays for the global mar- ket, including the most demanding American market. Vials 2 facility